Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

NCT04209205 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: AIN457 6 mg/kg i.v.
DRUG: Placebo
DRUG: AIN457 3 mg/kg

Sponsor

Novartis Pharmaceuticals